Skip to main content
Retour
Watch Compare

Quoin Pharmaceuticals, Ltd.

Qualité des données : 83%
QNRX
Nasdaq Manufacturing Chemicals
5,90 €
▲ 0,16 € (2,79%)
Cap. Boursière: 10,19 M
Prix
5,65 €
Cap. Boursière
10,19 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -13,54 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-2364,66%
En dessous de la moyenne du secteur (-53,41%)
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio1,04
Interest CoverageN/A

Valorisation

PE (TTM)
-0,64
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,6 -1,5
P/B — 1,6
ROE % -2364,7 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -15,80 M
ROE -2364,66% ROA -206,11%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -13,54 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,04
Interest Coverage N/A Asset Turnover N/A
Working Capital 250 779 Tangible Book Value -1,62 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,64 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -132,88%
Market Cap 10,19 M Enterprise Value 8,36 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -7,51 OCF / Share -7,51
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85,68%
SBC-Adj. FCF -14,72 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — 0,0
Net Income -15,80 M -8,96 M -8,69 M -9,38 M -21,46 M
EPS (Diluted) — — — — -0,01
Gross Profit — — — — —
Operating Income — — — — —
EBITDA — — — — —
R&D Expenses 9,80 M 3,60 M 3,31 M 2,67 M 1,56 M
SG&A Expenses 6,49 M 5,93 M 6,07 M 6,58 M 4,50 M
D&A — — — — —
Interest Expense — — — — 1,09 M
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 20,39 M 15,71 M 12,17 M 14,46 M 9,36 M
Total Liabilities 7,27 M 6,50 M 6,51 M 7,05 M 8,70 M
Shareholders' Equity 13,12 M 9,20 M 5,66 M 7,41 M 657 032,0
Total Debt — — — — —
Cash & Equivalents 3,82 M 3,62 M 2,40 M 2,86 M 7,48 M
Current Assets 20,01 M 14,93 M 11,29 M 13,37 M 8,50 M
Current Liabilities 5,55 M 4,18 M 3,58 M 3,53 M —